Commerzbank Aktiengesellschaft FI Buys 2,863 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Commerzbank Aktiengesellschaft FI boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 27.4% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 13,326 shares of the biopharmaceutical company's stock after buying an additional 2,863 shares during the quarter. Commerzbank Aktiengesellschaft FI's holdings in Gilead Sciences were worth $1,493,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Smallwood Wealth Investment Management LLC purchased a new stake in shares of Gilead Sciences during the 1st quarter worth about $25,000. Goodman Advisory Group LLC bought a new stake in Gilead Sciences during the first quarter valued at about $29,000. Core Alternative Capital boosted its holdings in Gilead Sciences by 370.8% during the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock valued at $34,000 after acquiring an additional 241 shares during the period. Annis Gardner Whiting Capital Advisors LLC raised its position in shares of Gilead Sciences by 158.8% during the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock valued at $33,000 after buying an additional 216 shares during the last quarter. Finally, Investment Research & Advisory Group Inc. raised its position in shares of Gilead Sciences by 33.3% during the first quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company's stock valued at $45,000 after buying an additional 100 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company's stock.

Analyst Ratings Changes

Several analysts have weighed in on GILD shares. Needham & Company LLC reaffirmed a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. Morgan Stanley upped their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research report on Friday, April 25th. Oppenheimer reduced their target price on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday, April 25th. JPMorgan Chase & Co. upped their target price on shares of Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research report on Thursday, March 27th. Finally, Cantor Fitzgerald assumed coverage on shares of Gilead Sciences in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 target price on the stock. Nine analysts have rated the stock with a hold rating, fourteen have issued a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $111.38.

Gilead Sciences Trading Down 0.5%

NASDAQ GILD traded down $0.58 on Friday, hitting $108.22. The company's stock had a trading volume of 6,627,889 shares, compared to its average volume of 7,664,713. The company has a quick ratio of 1.23, a current ratio of 1.37 and a debt-to-equity ratio of 1.16. Gilead Sciences, Inc. has a 1-year low of $70.78 and a 1-year high of $119.96. The company's 50-day moving average is $108.81 and its 200 day moving average is $105.17. The firm has a market cap of $134.62 billion, a PE ratio of 22.78, a PEG ratio of 0.71 and a beta of 0.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.04. The business had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. Gilead Sciences's revenue was down .3% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.32) earnings per share. As a group, analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, June 27th. Investors of record on Friday, June 13th were given a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.92%. The ex-dividend date of this dividend was Friday, June 13th. Gilead Sciences's payout ratio is currently 66.53%.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction that occurred on Tuesday, July 15th. The shares were sold at an average price of $111.03, for a total transaction of $277,575.00. Following the completion of the transaction, the chief financial officer owned 162,610 shares of the company's stock, valued at approximately $18,054,588.30. The trade was a 1.51% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Daniel Patrick O'day sold 10,000 shares of the company's stock in a transaction on Monday, June 30th. The stock was sold at an average price of $110.45, for a total transaction of $1,104,500.00. Following the completion of the transaction, the chief executive officer directly owned 615,725 shares in the company, valued at approximately $68,006,826.25. The trade was a 1.60% decrease in their position. The disclosure for this sale can be found here. Insiders sold 72,000 shares of company stock valued at $7,844,775 over the last ninety days. Company insiders own 0.27% of the company's stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.